Patent intelligence · US
US 2025002606
Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA
Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA
Patent details — US 2025002606
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 2, 2025
- Expiration
- Dec 28, 2044
- Applicant
- BAVARIAN NORDIC AS [DK]
- CPC classes
- A61K/3939541, A61K/3939558
Quick answer
US 2025002606 (Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA) is held by BAVARIAN NORDIC AS [DK]. Status: granted. Granted Jan 2, 2025. Expires Dec 28, 2044 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAVARIAN NORDIC AS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/3939541, A61K/3939558
More from BAVARIAN NORDIC AS [DK]
Related pharmaceutical patents in our USPTO index.
-
WO 2026104630
MÉTHODE DE SÉLECTION DOMINANTE PERMANENTE POUR LA GÉNÉRATION DU VIRUS ANKARA DE LA VACCINE MODIFIÉ RECOMBINANT (MVA)
granted -
WO 2026062034
NANOPARTICULES DE PROTÉINE AFFICHANT DES ANTIGÈNES DE MALADIE DE LYME
granted -
WO 2025238218
VECTEURS VIRAUX CODANT POUR DES NANOPARTICULES DE PROTÉINE D'AFFICHAGE D'ANTIGÈNE
granted -
WO 2025238221
VECTEURS VIRAUX CODANT POUR DES NANOPARTICULES DE PROTÉINE À PRÉSENTATION D'ANTIGÈNES MULTIPLES
granted -
WO 2025238220
ACIDES NUCLÉIQUES POUR LA VACCINATION CODANT POUR DES NANOPARTICULES DE PROTÉINE DE PRÉSENTATION DES ANTIGÈNES
granted -
WO 2025238219
VIRUS MODIFIÉ DE LA VACCINE ANKARA (MVA) CODANT POUR DES NANOPARTICULES PROTÉIQUES PRÉSENTANT DES ANTIGÈNES
granted -
WO 2024188801
UTILISATION DE LIGNÉES CELLULAIRES DE CAILLE POUR PRODUCTION DE POXVIRUS
granted
Frequently asked questions
What is US patent 2025002606?
US 2025002606 (Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA) is held by BAVARIAN NORDIC AS [DK]. Status: granted. Granted Jan 2, 2025. Expires Dec 28, 2044 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2025002606?
BAVARIAN NORDIC AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2025002606 expire?
Our index shows an expiration date of Dec 28, 2044 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.